Published in Lancet on January 11, 2003
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis (2008) 2.05
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol (2008) 1.93
How evidence-based are the recommendations in evidence-based guidelines? PLoS Med (2007) 1.60
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Mechanisms of progression of chronic kidney disease. Pediatr Nephrol (2007) 1.52
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol (2008) 1.38
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol (2008) 1.36
The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol (2008) 1.15
Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol (2008) 1.11
Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol (2009) 1.03
The COOPERATE trial: a letter of concern. Lancet (2008) 1.03
The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrol (2011) 1.03
Therapeutic approach to FSGS in children. Pediatr Nephrol (2006) 1.01
Combination therapy in hypertension: An update. Diabetol Metab Syndr (2010) 0.99
Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol (2008) 0.99
Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol (2008) 0.98
Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol (2007) 0.97
MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis. Transfus Med Hemother (2010) 0.94
Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev (2011) 0.94
Nephrotic syndrome in adults. BMJ (2008) 0.94
Astragalus mongholicus ameliorates renal fibrosis by modulating HGF and TGF-beta in rats with unilateral ureteral obstruction. J Zhejiang Univ Sci B (2009) 0.93
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol (2008) 0.93
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag (2007) 0.93
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
Treatment of hypertension in children and adolescents. Pediatr Nephrol (2007) 0.91
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Ther Adv Chronic Dis (2013) 0.88
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol (2004) 0.87
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis (2010) 0.85
Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag (2009) 0.84
Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol (2006) 0.84
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. J Womens Health (Larchmt) (2008) 0.83
Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83
Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp Diabetes Res (2012) 0.83
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol (2009) 0.82
Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol (2008) 0.81
Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephrourol Mon (2014) 0.81
Comparative efficacy and safety of triple therapy (ramipril, telmisartan, hydrochlorothiazide) vs dual anti hypertensive therapy (ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patients. J Clin Diagn Res (2014) 0.81
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol (2008) 0.81
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.80
Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail (2007) 0.80
Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp Ther Med (2013) 0.79
Cyprinus carpio Decoction Improves Nutrition and Immunity and Reduces Proteinuria through Nephrin and CD2AP Expressions in Rats with Adriamycin-Induced Nephropathy. Evid Based Complement Alternat Med (2012) 0.79
Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. Br J Clin Pharmacol (2011) 0.79
Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor. Clin Exp Nephrol (2006) 0.79
Intratubular Renin-Angiotensin System in Hypertension. Curr Hypertens Rev (2006) 0.78
Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1. Pediatr Nephrol (2013) 0.78
Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. Can J Cardiol (2007) 0.78
Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med (2008) 0.78
Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med (2008) 0.78
ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease. Open Access Emerg Med (2010) 0.77
ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Expert Opin Pharmacother (2003) 0.77
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr Diab Rep (2010) 0.77
Resistant hypertension: current status, future challenges. Int J Prev Med (2014) 0.77
Treatment of hypertension in patients with nondiabetic chronic kidney disease. Can J Cardiol (2007) 0.76
Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease. Clin J Am Soc Nephrol (2008) 0.76
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. Clin Exp Nephrol (2008) 0.76
Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol (2012) 0.76
The COOPERATE trial. Lancet (2003) 0.76
Blood pressure and diabetic nephropathy. Diabetes Care (2010) 0.76
Cardiac and vascular protection: the potential of ONTARGET. Medscape J Med (2008) 0.75
Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy. Int J Endocrinol (2015) 0.75
High dose Losartan and ACE gene polymorphism in IgA nephritis. Genomic Med (2009) 0.75
Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results. Hypertension (2008) 0.75
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report. J Med Case Rep (2010) 0.75
The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol (2017) 0.75
Retracted Combination ACE inhibitor and angiotensin-receptor blocker therapy was better than monotherapy in nondiabetic renal disease. ACP J Club (2003) 0.75
Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. High Blood Press Cardiovasc Prev (2013) 0.75
Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. F1000 Med Rep (2009) 0.75
The COOPERATE trial. Lancet (2003) 0.75
Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease? Cardiovasc J Afr (2010) 0.75
Retarding the progression of chronic kidney disease with renin angiotensin system blockade. Indian J Nephrol (2012) 0.75
Renin inhibitors in diabetes and hypertension: an update. EXCLI J (2014) 0.75
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol (2016) 0.75
The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis. PLoS One (2015) 0.75
Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria. Pediatr Nephrol (2005) 0.75
Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. Clin J Am Soc Nephrol (2007) 0.75
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides Med J (2015) 0.75
Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease. J Nephropharmacol (2014) 0.75
Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? BMC Nephrol (2012) 0.75
The COOPERATE trial. Lancet (2003) 0.75
Living high training low induces physiological cardiac hypertrophy accompanied by down-regulation and redistribution of the renin-angiotensin system. Acta Pharmacol Sin (2013) 0.75
Renal failure (chronic). BMJ Clin Evid (2011) 0.75
Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats. Biomed Rep (2014) 0.75
ACE inhibitors and ARBs: one or the other--not both--for high-risk patients. J Fam Pract (2009) 0.75
On the occasion of world kidney day 2016; work together to better protect the kidney. J Nephropathol (2015) 0.75
Renal interstitial fibrosis and Angiotensin inhibition. Electrolyte Blood Press (2006) 0.75
The COOPERATE trial. Lancet (2003) 0.75
Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol (2005) 0.75
[Novel guidelines for antihypertensive treatment. Proven and new]. Internist (Berl) (2005) 0.75
Renal failure and ACE inhibition: how much is too much? Z Kardiol (2005) 0.75
Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease. Clin Exp Nephrol (2009) 0.75
Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med (2002) 2.61
A strict low protein diet during the predialysis period suppresses peritoneal permeability at induction of peritoneal dialysis. Perit Dial Int (2009) 2.58
EF-G2mt is an exclusive recycling factor in mammalian mitochondrial protein synthesis. Mol Cell (2009) 1.82
Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J (2003) 1.53
Structure and function of the chalcone synthase superfamily of plant type III polyketide synthases. Nat Prod Rep (2010) 1.47
Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int (2004) 1.42
Portal vein thrombosis in adult-onset Still's disease: a case report and literature review. Rheumatol Int (2009) 1.42
Physiologic roles of 11beta-hydroxysteroid dehydrogenase type 2 in kidney. Metabolism (2006) 1.40
Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest (2007) 1.40
Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy--prospective multicenter cohort study. Int J Cardiol (2013) 1.40
Inverse Correlation Between Calcium Accumulation and the Expansion Rate of Abdominal Aortic Aneurysms. Circ J (2015) 1.38
Relationships between Causes of Fever of Unknown Origin and Inflammatory Markers: A Multicenter Collaborative Retrospective Study. Intern Med (2015) 1.38
Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res (2004) 1.36
The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J (2008) 1.30
Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol (2005) 1.28
Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol (2008) 1.28
A plant type III polyketide synthase that produces pentaketide chromone. J Am Chem Soc (2005) 1.14
Somatic mutations in cerebral cortical malformations. N Engl J Med (2014) 1.10
Altered patterns of gene expression specific to thoracic aortic aneurysms: microarray analysis of surgically resected specimens. Int Heart J (2005) 1.07
Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol (2010) 0.99
Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol (2003) 0.98
A novel channelopathy in pulmonary arterial hypertension. N Engl J Med (2013) 0.98
Predictors of mortality after emergency or elective repair of abdominal aortic aneurysm in a Japanese population. Heart Vessels (2012) 0.97
An acridone-producing novel multifunctional type III polyketide synthase from Huperzia serrata. FEBS J (2007) 0.96
Engineered biosynthesis of plant polyketides: manipulation of chalcone synthase. Org Lett (2006) 0.94
Reversible posterior leukoencephalopathy syndrome after blood transfusion in a patient with end-stage renal disease. Clin Exp Nephrol (2011) 0.93
Structure function analysis of benzalacetone synthase from Rheum palmatum. Bioorg Med Chem Lett (2007) 0.93
Protein kinase C (PKC) beta modulates serine phosphorylation of insulin receptor substrate-1 (IRS-1)--effect of overexpression of PKCbeta on insulin signal transduction. Endocr Res (2004) 0.92
Effect of fasting on PPARgamma and AMPK activity in adipocytes. Diabetes Res Clin Pract (2008) 0.92
The metabolic syndrome and DYRK1B. N Engl J Med (2014) 0.91
Actin -related protein 3 (Arp3) is mutated in proteinuric BUF/Mna rats. Mamm Genome (2007) 0.89
Diagnostic workup for fever of unknown origin: a multicenter collaborative retrospective study. BMJ Open (2013) 0.88
Speckle tracking global strain rate E/E' predicts LV filling pressure more accurately than traditional tissue Doppler E/E'. Echocardiography (2011) 0.88
Cytotoxic tetramic acid derivative produced by a plant type-III polyketide synthase. J Am Chem Soc (2011) 0.88
Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology (2013) 0.87
Serum levels of IgG4 and soluble interleukin-2 receptor in patients with coronary artery disease. Clin Chim Acta (2011) 0.86
Application of periodic acid-Schiff fluorescence emission for immunohistochemistry of living mouse renal glomeruli by an "in vivo cryotechnique". Arch Histol Cytol (2006) 0.86
Collagenofibrotic glomerulopathy with a widespread expression of type-V collagen. Virchows Arch (2002) 0.86
Structure-based engineering of a plant type III polyketide synthase: formation of an unnatural nonaketide naphthopyrone. J Am Chem Soc (2007) 0.86
Prenylation of a nonaromatic carbon of indolylbutenone by a fungal indole prenyltransferase. Org Lett (2012) 0.85
Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels (2012) 0.85
Inverse association between the existence of coronary artery disease and progression of abdominal aortic aneurysm. Atherosclerosis (2012) 0.85
Mouse brain IgG-like immunoreactivity: strain-specific occurrence in microglia and biochemical identification of IgG. J Comp Neurol (2005) 0.84
Evaluating Japanese patients with the Marfan syndrome using high-throughput microarray-based mutational analysis of fibrillin-1 gene. Am J Cardiol (2011) 0.84
Prediction of coronary artery stenosis using strain imaging diastolic index at rest in patients with preserved ejection fraction. J Cardiol (2011) 0.84
Spectral pattern of urinary water as a biomarker of estrus in the giant panda. Sci Rep (2012) 0.83
Genome-wide association study of coronary artery disease. Int J Hypertens (2010) 0.83
Retinopathy progression in type 2 diabetes. N Engl J Med (2010) 0.83
Molecular cloning and characterization of copper amine oxidase from Huperzia serrata. Bioorg Med Chem Lett (2012) 0.83
Cloning and structure-function analyses of quinolone- and acridone-producing novel type III polyketide synthases from Citrus microcarpa. J Biol Chem (2013) 0.83
Glycyrrhizic acid suppresses type 2 11 beta-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol (2002) 0.83
Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 0.83
Resistance to neointimal hyperplasia and fatty streak formation in mice with adrenomedullin overexpression. Arterioscler Thromb Vasc Biol (2002) 0.82
Reproducibility and diagnostic accuracy of three-layer speckle tracking echocardiography in a swine chronic ischemia model. Echocardiography (2011) 0.82
Novel type III polyketide synthases from Aloe arborescens. FEBS J (2009) 0.82
Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy. Intern Med (2012) 0.81
Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.81
Structure-based engineering of benzalacetone synthase. Bioorg Med Chem Lett (2010) 0.81
Dehydroepiandrosterone reduces preadipocyte proliferation via androgen receptor. Am J Physiol Endocrinol Metab (2012) 0.81
Enzymatic formation of unnatural novel chalcone, stilbene, and benzophenone scaffolds by plant type III polyketide synthase. Org Lett (2009) 0.81
Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis. J Nephrol (2013) 0.81
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res (2013) 0.80
Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis (2003) 0.80
TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol (2015) 0.80
HSD11B2 CA-repeat and sodium balance. Hypertens Res (2013) 0.80
Reversible choreoathetosis after the administration of ceftriaxone sodium in patients with end-stage renal disease. Am J Med Sci (2010) 0.80
A bacterial elongation factor G homologue exclusively functions in ribosome recycling in the spirochaete Borrelia burgdorferi. Mol Microbiol (2010) 0.80
A Case of Subepidermal Blistering Disease with Autoantibodies to Multiple Laminin Subunits who Developed Later Autoantibodies to Alpha-5 Chain of Type IV Collagen Associated with Membranous Glomerulonephropathy. Acta Derm Venereol (2015) 0.80
Smooth-muscle calponin in mesangial cells: regulation of expression and a role in suppressing glomerulonephritis. J Am Soc Nephrol (2002) 0.80
Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients. Clin Exp Nephrol (2011) 0.80
A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population. Atherosclerosis (2003) 0.80
Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas. J Clin Endocrinol Metab (2005) 0.79
Effect of dehydroepiandrosterone on insulin sensitivity in Otsuka Long-Evans Tokushima-fatty rats. Acta Diabetol (2007) 0.79
Effect of nematode Trichinella infection on glucose tolerance and status of macrophage in obese mice. Endocr J (2013) 0.79
Myeloperoxidase-antineutrophil cytoplasmic antibody-related crescentic glomerulonephritis after treatment for clinically amyopathic dermatomyositis: a coincidental combination or not? Clin Exp Nephrol (2011) 0.79
Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab (2002) 0.79
Pioglitazone enhances small-sized adipocyte proliferation in subcutaneous adipose tissue. Endocr J (2012) 0.79
[2+1] Cycloaddition of nitrene onto C60 revisited: interconversion between an aziridinofullerene and an azafulleroid. Angew Chem Int Ed Engl (2008) 0.78
Effect of 1 alpha,25-dihydroxy vitamin D3 and vitamin E on insulin-induced glucose uptake in rat adipocytes. Diabetes Res Clin Pract (2002) 0.78
Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy. Nephrol Dial Transplant (2003) 0.78
Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. J Hypertens (2005) 0.78
Lithium toxicity precipitated by thyrotoxicosis due to silent thyroiditis: cardiac arrest, quadriplegia, and coma. Thyroid (2013) 0.78
Studies on unfolded beta-microglobulin at C-terminal in dialysis-related amyloidosis. Kidney Int (2005) 0.78
Inhibition of PKCbeta improves glucocorticoid-induced insulin resistance in rat adipocytes. IUBMB Life (2002) 0.78
Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. J Clin Endocrinol Metab (2003) 0.78
Impact of the new risk stratification in the 2011 Japanese Society of Nephrology clinical guidelines for IgA nephropathy on incidence of early clinical remission with tonsillectomy plus steroid pulse therapy. Clin Exp Nephrol (2014) 0.77
Systemic AA amyloidosis in a patient with lung metastasis from renal cell carcinoma. Amyloid (2012) 0.77
Coronary atherosclerotic lesions in patients with a ruptured abdominal aortic aneurysm. Heart Vessels (2014) 0.77